EBRT for Prostate Cancer Hikes Risk of Secondary Cancers
Naeem Bhojani, MD, of the
They identified 92 bladder cancers, 82 lung cancers, and 228 rectal cancers. After adjusting for age, baseline comorbidities, and year of treatment, EBRT predisposed to a threefold higher rate of bladder cancer and a nearly twofold higher rate of lung and rectal cancer.
“The increased rate of secondary malignancies after EBRT should be considered in localized prostate cancer treatment decision-making,” the authors concluded.